



MVP Health Care Medical Policy

Medicare Part B: Syfovre

Type of Policy: Medical Therapy

Prior Approval Date: 04/01/2026

Approval Date: 04/01/2026

Effective Date: 06/01/2026

Related Policies: Orphan Drug(s) and Biologicals

Refer to the MVP Medicare website for the Medicare Part D formulary and Part D policies.

Refer to relevant CMS LCDs/NCDs/Policy Articles for most up to date Medicare Part B guidance if available.

Drugs Requiring Prior Authorization under the medical benefit

J2781 Syfovre (pegcetacoplan) solution for injection

Overview

Syfovre (pegcetacoplan) solution for intravitreal injection is a parenteral complement (C3) inhibitor. It is FDA approved for the treatment of geographic atrophy (GA) secondary to the dry advanced form of age-related macular degeneration (AMD). GA is an irreversible eye disease.

Indications/Criteria

Geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Syfovre may be considered for coverage when:

- Prescribed and administered by an ophthalmologist
- Chart notes confirming the diagnosis of GA secondary to AMD
- Best-corrected visual acuity (BCVA) ≥ 24 letters using Early Treatment Diabetic Retinopathy Study (ETDRS) charts OR approximate Snellen equivalent of 20/320

Initial approval will be for 6 months.

Subsequent approvals will be for up to 1 year duration and require documentation of clinical benefit.

Exclusions

The use of Syfovre will not be covered for the following situations:

- Members with ocular or periocular infections
- Members with active intraocular inflammation
- Age, dosage, and/or frequency outside of the FDA approved package labeling
- GA secondary to a condition other than AMD such as Stargardt disease in either eye

References

1. Syfovre (pegcetacoplan). Clinical Pharmacology. Revised 10/14/2025. Accessed 02/26/2026.
2. Syfovre (pegcetacoplan). Prescribing Information. Apellis Pharmaceuticals, Inc. Waltham, MA. Revised 07/2025. [PI SYFOVRE.pdf \(apellis.com\)](#).
3. Prevent Blindness (n.d.). *Eye Diseases & Conditions*. Retrieved 02/26/2026, from <https://preventblindness.org/geographic-atrophy/>
4. Age-related macular degeneration Preferred Practice Pattern 2024. *American Academy of Ophthalmology*. Retrieved February 6, 2026, from <https://www.aao.org/education/preferred-practice-pattern/age-related-macular-degeneration-ppp>